Regulus Therapeutics, the microRNA drug joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, has filed with US regulators to begin selling its shares on the public market.
The move to float its shares has been expected for some time, as Regulus in 2010 began looking to fill positions with duties related to the activities of a public company (GSN 9/23/2010).
In a filing with the US Securities and Exchange Commission last week, Regulus said it has signed on Lazard Capital Markets, Cowen and Company, and BMO Capital Markets to jointly manage the proposed initial public offering.
Specific details, including the number of shares to be offered, the price range of the offering, and when the IPO might occur were not provided.
In the filing, Regulus did provide a few details about its business plan, including its pipeline of miRNA-targeting drugs.
According to the company, it has five programs in development. The first targets miR-21 to treat liver cancer and is being developed in collaboration with Sanofi. It is also working with Sanofi on the same miRNA as a treatment for kidney fibrosis.
Regulus' most advanced effort is its hepatitis C program, which targets miR-122 and is being advanced with GlaxoSmithKline. It is also working with AstraZeneca on targeting miR-33 for atherosclerosis, and has an in-house program in glioblastoma that targets miR-10b.